Skip to main content
. 2018 Aug 29;10:3057–3067. doi: 10.2147/CMAR.S167781

Table 2.

CPNE3 expression and clinical outcome of sorafenib treatment

Characters CPNE3 mRNA expression
P
High (n=68) Low (n=73)
TTP 8.0 11.0 0.0015
7.2–10.8 months 10.9–13.1 months
OS 10.0 14.0 <0.0001
8.1–12.1 months 12.7–15.3 months
Overall response rate (CR + PR) 4 (5.9%) 9 (12.3%)
Disease control rate (CR + PR + SD) 16 (23.5%) 32 (43.8%)

Abbreviations: TTP, time to progress; OS, overall survival; PR, partial remission; CR, complete remission; SD, stable disease.